Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Abstract 1202: Tumor cell intrinsic STING signaling demonstrates minimal contribution to the anti-tumor response elicited by the STING agonist ADU-S100 (MIW815)

Leticia Corrales, Antony L. Desbien, Kelsey E. Sivick Gauthier, Weiwen Deng, Tamara Schroeder, Gabrielle L. Reiner, Natalie Surh, Brian Francica, Ken Metchette, Chudi O. Ndubaku, Jeffrey M. McKenna, Yan Feng, Lianxing Zheng, Steven L. Bender, Charles Y. Cho, Andrea van Elsas, Meredith L. Leong, Sarah M. McWhirter

Cancer Res (2019) 79 (13_Supplement): 1202.

https://doi.org/10.1158/1538-7445.AM2019-1202

Published: 01 July 2019

View article titled, Abstract 1202: Tumor cell intrinsic STING signaling demonstrates minimal contribution to the anti-tumor response elicited by the STING agonist ADU-S100 (MIW815)

Journal Articles

Abstract 2273: A machine learning approach to identify a peripheral prognostic cytokine signature via nivolumab clearance in patients with advanced melanoma

Rui Wang, Xiao Shao, Junying Zheng, Abdel Saci, Max Qian, Irene Pak, Amit Roy, Akintunde Bello, Jasmine Rizzo, Fareeda Hosein, Rebecca A. Moss, Megan Wind-Rotolo, Yan Feng

Cancer Res (2019) 79 (13_Supplement): 2273.

https://doi.org/10.1158/1538-7445.AM2019-2273

Published: 01 July 2019

View article titled, Abstract 2273: A machine learning approach to identify a peripheral prognostic cytokine signature via nivolumab clearance in patients with advanced melanoma

Journal Articles

Abstract LB-127: From bench to bedside: Exploring OX40 receptor modulation in a phase 1/2a study of the OX40 costimulatory agonist BMS-986178 ± nivolumab (NIVO) or ipilimumab (IPI) in patients with advanced solid tumors

Cancer Res (2018) 78 (13_Supplement): LB-127.

https://doi.org/10.1158/1538-7445.AM2018-LB-127

Published: 01 July 2018

View article titled, Abstract LB-127: From bench to bedside: Exploring OX40 receptor modulation in a phase 1/2a study of the OX40 costimulatory agonist BMS-986178 ± nivolumab (NIVO) or ipilimumab (IPI) in patients with advanced solid tumors

Journal Articles

Abstract 5420: PGAM1-REDD1 pathway promotes paclitaxel resistance through enhancing aerobic glycolysis in ovarian cancer cells

Yan Feng, Weiguo Lv, Xing Xie, Yan Yu

Cancer Res (2017) 77 (13_Supplement): 5420.

https://doi.org/10.1158/1538-7445.AM2017-5420

Published: 01 July 2017

View article titled, Abstract 5420: PGAM1-REDD1 pathway promotes paclitaxel resistance through enhancing aerobic glycolysis in ovarian cancer cells

Journal Articles

Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types

Xiaochen Zhao, Vijay Ivaturi, Mathangi Gopalakrishnan, Jun Shen, Yan Feng, Paul Statkevich, Eric Richards, Michelle Rashford, Vicki Goodman, Joga Gobburu, Akintunde Bello, Amit Roy, Shruti Agrawal

Cancer Res (2017) 77 (13_Supplement): CT101.

https://doi.org/10.1158/1538-7445.AM2017-CT101

Published: 01 July 2017

View article titled, Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types

Journal Articles

Abstract SY39-02: Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity

Cancer Res (2016) 76 (14_Supplement): SY39-02.

https://doi.org/10.1158/1538-7445.AM2016-SY39-02

Published: 15 July 2016

View article titled, Abstract SY39-02: Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity

Journal Articles

Abstract 4631: SCFFbxo7 ubiquitin ligase targets cereblon to limit the anti-myeloma activity of IMiDs

Jiye Liu, Wenrong Zhou, Yan Feng, Tianyu Song, Shaobing Gao, Junfeng Wu, Zhenggang Peng, Yong Cang

Cancer Res (2016) 76 (14_Supplement): 4631.

https://doi.org/10.1158/1538-7445.AM2016-4631

Published: 15 July 2016

View article titled, Abstract 4631: SCFFbxo7 ubiquitin ligase targets cereblon to limit the anti-myeloma activity of IMiDs

Journal Articles

Abstract 1445: STING activation in the tumor microenvironment with a synthetic human STING-activating cyclic dinucleotide leads to potent anti-tumor immunity

Cancer Res (2016) 76 (14_Supplement): 1445.

https://doi.org/10.1158/1538-7445.AM2016-1445

Published: 15 July 2016

View article titled, Abstract 1445: STING activation in the tumor microenvironment with a synthetic human STING-activating cyclic dinucleotide leads to potent anti-tumor immunity

Journal Articles

Natural Product Vibsanin A Induces Differentiation of Myeloid Leukemia Cells through PKC Activation

Cancer Res (2016) 76 (9): 2698–2709.

https://doi.org/10.1158/0008-5472.CAN-15-1616

Published: 01 May 2016

View article titled, Natural Product Vibsanin A Induces Differentiation of Myeloid Leukemia Cells through PKC Activation

Includes: Supplementary data

Journal Articles

Abstract CT128: Association between tumor shrinkage and overall survival in advanced melanoma patients with nivolumab in combination with ipilimumab

Yan Feng, Manish Gupta, Shruti Agrawal, Amit Roy

Cancer Res (2015) 75 (15_Supplement): CT128.

https://doi.org/10.1158/1538-7445.AM2015-CT128

Published: 01 August 2015

View article titled, Abstract CT128: Association between tumor shrinkage and overall survival in advanced melanoma patients with nivolumab in combination with ipilimumab

Journal Articles

Abstract 3718: Adaptive drug escape of EML4-ALK lung cancer against targeted ALK inhibitor involving TGFβ2-mitochondrial priming

Lihong Yin, Wei Zhang, Ivy Shi, Yan Feng, Rakesh Bagai, Daniel Lindner, Patrick C. Ma

Cancer Res (2014) 74 (19_Supplement): 3718.

https://doi.org/10.1158/1538-7445.AM2014-3718

Published: 01 October 2014

View article titled, Abstract 3718: Adaptive drug escape of EML4-ALK lung cancer against targeted ALK inhibitor involving TGFβ2-mitochondrial priming

Journal Articles

Abstract 1835: Transcriptome and metabolome reprogramming in EGFR-mutant NSCLC early adaptive drug-escape against erlotinib

Patrick C. Ma, Praveena S. Thiagarajan, Patrick Leahy, Rakesh Bagai, Ivy Shi, Wei Zhang, Yan Feng, Martina L. Veigl, Daniel Lindner, David Danielpour, Lihong Yin

Cancer Res (2014) 74 (19_Supplement): 1835.

https://doi.org/10.1158/1538-7445.AM2014-1835

Published: 01 October 2014

View article titled, Abstract 1835: Transcriptome and metabolome reprogramming in EGFR-mutant NSCLC early adaptive drug-escape against erlotinib

Journal Articles

Abstract B23: Identification of TMPRSS2:ERG-dependent regulators of AR function and differentiation status in prostate cancer

Zineb Mounir, Raymond Pagliarini, Fallon Lin, Markus Schirle, Justin Klekota, Yan Feng, Anke Hartung, Aron Jaffe, Gilles Buchwalter, Myles Brown

Cancer Res (2012) 72 (4_Supplement): B23.

https://doi.org/10.1158/1538-7445.PRCA2012-B23

Published: 09 May 2013

View article titled, Abstract B23: Identification of TMPRSS2:ERG-dependent regulators of AR function and differentiation status in prostate cancer

Journal Articles

Abstract 2374: Tumoral MET expression and plasma HGF level in patients with ALK 2p23 fusion driven lung cancer.

Yan Feng, Eugen Minca, Wei Zhang, Lihong Yin, Nathan Pennell, Carol Farver, Raymond Tubbs, Angen Liu, Patrick Ma

Cancer Res (2013) 73 (8_Supplement): 2374.

https://doi.org/10.1158/1538-7445.AM2013-2374

Published: 15 April 2013

View article titled, Abstract 2374: Tumoral MET expression and plasma HGF level in patients with ALK 2p23 fusion driven lung cancer.

Journal Articles

Abstract 4455: Studies of early adaptive resistance in mutant-EGFR and EML4-ALK addicted non-small cell lung cancer in escape against small molecule inhibitors.

Lihong Yin, Ivy Shi, Wei Zhang, Rakesh Bagai, Yan Feng, Patrick C. Ma

Cancer Res (2013) 73 (8_Supplement): 4455.

https://doi.org/10.1158/1538-7445.AM2013-4455

Published: 15 April 2013

View article titled, Abstract 4455: Studies of early adaptive resistance in mutant-EGFR and EML4-ALK addicted non-small cell lung cancer in escape against small molecule inhibitors.

Journal Articles

The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

Yan Feng, Ye Wang, Zuoyun Wang, Zhaoyuan Fang, Fei Li, Yijun Gao, Hongyan Liu, Tian Xiao, Fuming Li, Yang Zhou, Qiwei Zhai, Xiaolong Liu, Yihua Sun, Nabeel Bardeesy, Kwok-kin Wong, Haiquan Chen, Zhi-qi Xiong, Hongbin Ji

Cancer Res (2012) 72 (24): 6502–6511.

https://doi.org/10.1158/0008-5472.CAN-12-1909

Published: 16 December 2012

View article titled, The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

Includes: Supplementary data

Journal Articles

Helicobacter hepaticus–Induced Liver Tumor Promotion Is Associated with Increased Serum Bile Acid and a Persistent Microbial-Induced Immune Response

Alexis García, Yu Zeng, Sureshkumar Muthupalani, Zhongming Ge, Amanda Potter, Melissa W. Mobley, Chakib Boussahmain, Yan Feng, John S. Wishnok, James G. Fox

Cancer Res (2011) 71 (7): 2529–2540.

https://doi.org/10.1158/0008-5472.CAN-10-1975

Published: 31 March 2011

View article titled, Helicobacter hepaticus–Induced Liver Tumor Promotion Is Associated with Increased Serum Bile Acid and a Persistent Microbial-Induced Immune Response

Includes: Supplementary data

Journal Articles

Hepatocellular Carcinoma Associated with Liver-Gender Disruption in Male Mice

Arlin B. Rogers, Elizabeth J. Theve, Yan Feng, Rebecca C. Fry, Koli Taghizadeh, Kristen M. Clapp, Chakib Boussahmain, Kathleen S. Cormier, James G. Fox

Cancer Res (2007) 67 (24): 11536–11546.

https://doi.org/10.1158/0008-5472.CAN-07-1479

Published: 18 December 2007

View article titled, Hepatocellular Carcinoma Associated with Liver-Gender Disruption in Male Mice

Includes: Supplementary data

Journal Articles

Liver-gender mosaicism correlates with hepatocellular carcinoma in male mice

Arlin Rogers, Elizabeth Theve, Yan Feng, James Fox

Cancer Res (2007) 67 (9_Supplement): 2425.

Published: 01 May 2007

View article titled, Liver-gender mosaicism correlates with hepatocellular carcinoma in male mice

Journal Articles

CD4⁺CD25⁺ Regulatory Lymphocytes Require Interleukin 10 to Interrupt Colon Carcinogenesis in Mice

Susan E. Erdman, Varada P. Rao, Theofilos Poutahidis, Melanie M. Ihrig, Zhongming Ge, Yan Feng, Michal Tomczak, Arlin B. Rogers, Bruce H. Horwitz, James G. Fox

Cancer Res (2003) 63 (18): 6042–6050.

Published: 01 October 2003

View article titled, CD4+CD25+ Regulatory Lymphocytes Require Interleukin 10 to Interrupt Colon Carcinogenesis in Mice

NARROW

Abstract 1202: Tumor cell intrinsic STING signaling demonstrates minimal contribution to the anti-tumor response elicited by the STING agonist ADU-S100 (MIW815)

Abstract 2273: A machine learning approach to identify a peripheral prognostic cytokine signature via nivolumab clearance in patients with advanced melanoma

Abstract LB-127: From bench to bedside: Exploring OX40 receptor modulation in a phase 1/2a study of the OX40 costimulatory agonist BMS-986178 ± nivolumab (NIVO) or ipilimumab (IPI) in patients with advanced solid tumors

Abstract 5420: PGAM1-REDD1 pathway promotes paclitaxel resistance through enhancing aerobic glycolysis in ovarian cancer cells

Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types

Abstract SY39-02: Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity

Abstract 4631: SCFFbxo7 ubiquitin ligase targets cereblon to limit the anti-myeloma activity of IMiDs

Abstract 1445: STING activation in the tumor microenvironment with a synthetic human STING-activating cyclic dinucleotide leads to potent anti-tumor immunity

Natural Product Vibsanin A Induces Differentiation of Myeloid Leukemia Cells through PKC Activation

Abstract CT128: Association between tumor shrinkage and overall survival in advanced melanoma patients with nivolumab in combination with ipilimumab

Abstract 3718: Adaptive drug escape of EML4-ALK lung cancer against targeted ALK inhibitor involving TGFβ2-mitochondrial priming

Abstract 1835: Transcriptome and metabolome reprogramming in EGFR-mutant NSCLC early adaptive drug-escape against erlotinib

Abstract B23: Identification of TMPRSS2:ERG-dependent regulators of AR function and differentiation status in prostate cancer

Abstract 2374: Tumoral MET expression and plasma HGF level in patients with ALK 2p23 fusion driven lung cancer.

Abstract 4455: Studies of early adaptive resistance in mutant-EGFR and EML4-ALK addicted non-small cell lung cancer in escape against small molecule inhibitors.

The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

Helicobacter hepaticus–Induced Liver Tumor Promotion Is Associated with Increased Serum Bile Acid and a Persistent Microbial-Induced Immune Response

Hepatocellular Carcinoma Associated with Liver-Gender Disruption in Male Mice

Liver-gender mosaicism correlates with hepatocellular carcinoma in male mice

CD4⁺CD25⁺ Regulatory Lymphocytes Require Interleukin 10 to Interrupt Colon Carcinogenesis in Mice

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only